The trial will enroll 48 healthy volunteers to assess the candidate’s safety, tolerability and pharmacokinetics. Results are expected later this year.
HRX-0215 targets MKK4, a key regulator of liver regeneration, and is the first representative of the company’s drug discovery platform to enter clinical testing.
The therapeutic concept was discovered by the company’s co-founder Prof. Zender during his time at the Helmholtz Centre for Infection Research (HZI) in Braunschweig and the Hannover Medical School (MHH), and is protected by respective IP. Ascenion GmbH, technology transfer partner of both institutes, has supported the project from the start.
Further information: HepaRegeniX’ press release